– Lesley Griffiths AM, Health Minister
Developing this technology in Wales means that Welsh patients will be treated here; at present around 65 patients a year travel to England for SRS treatment, and less than ten a year for SBRT.
Velindre plans to treat around 290 patients a year.
We know that SBRT leads to improved outcomes and survival rates, and this technology will enable Welsh patients to participate in more clinical trials.
£4.6m is being invested in new specialist cancer treatment technology by the Welsh Government.
The funding will go towards a 'more targeted form' of radiotherapy at the Velindre Cancer Centre in Cardiff, by minimising damage to surrounding tissues.
This will initially be used on lung cancer patients.
Velindre says the aim is to 'improve patient outcomes' by offering the treatment known as Stereotactic Body Radiotherapy to some patients whose lung lesions are currently inoperable, and who otherwise would be offered palliative care.